

# JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 71, ISSUE 2, PAGES 231–448

## FROM THE EDITOR'S DESK

### From the Editor's desk. . .

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 231

## OBITUARY

### In Memoriam: Valerio Nobili (1966–2019)

E. Bugianesi and M. Pinzani 235

## EDITORIALS

### Inflammation drives an altered phenotype of mucosal-associated invariant T cells in chronic hepatitis D virus infection

H. Kefalakes and B. Rehermann 237

### Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?

F. Durand, M. Pavesi and R. Cheung 240

### Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses

J.M. O'Rourke, D.A. Patten and S. Shetty 243

### Referral pathways for NAFLD fibrosis in primary care – No longer a 'needle in a haystack'

M.J. Armstrong and G. Marchesini 246

### Hepatic fat: Pathogenic trigger or passenger?

M.C. Ryan and S. Zelber-Sagi 249

## RESEARCH ARTICLES

### Viral Hepatitis

#### KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B

R.S. Wijaya, S.A. Read, S. Schibeci, M. Eslam, M.K. Azardaryany, K. El-Khobar, D. van der Poorten, R. Lin, L. Yuen, V. Lam, J. George, M.W. Douglas and G. Ahlenstiel 252

#### Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

G. Cabibbo, C. Celsa, V. Calvaruso, S. Petta, I. Cacciola, M.R. Cannavò, S. Madonia, M. Rossi, B. Magro, F. Rini, M. Distefano, L. Larocca, T. Prestileo, G. Malizia, G. Bertino, F. Benanti, A. Licata, I. Scalisi, G. Mazzola, M.A. Di Rosolini, G. Alaimo, A. Averna, F. Cartabellotta, N. Alessi, S. Guastella, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, F. Trevisani, A. Craxì, V. Di Marco, C. Cammà and on behalf of Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group 265

#### Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies

G. Wandeler, E. Mauron, A. Atkinson, J.-F. Dufour, D. Kraus, P. Reiss, L. Peters, F. Dabis, J. Fehr, E. Bernasconi, M. van der Valk, C. Smit, L.K. Gjørde, J. Rockstroh, D. Neau, F. Bonnet, A. Rauch and on behalf of the Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort 274

#### Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia

M. Alavi, M.G. Law, H. Valerio, J. Grebely, J. Amin, B. Hajarizadeh, C. Selvey, J. George and G.J. Dore 281

#### Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells

A. König, J. Yang, E. Jo, K.H.P. Park, H. Kim, T.T. Than, X. Song, X. Qi, X. Dai, S. Park, D. Shum, W.-S. Ryu, J.-H. Kim, S.K. Yoon, J.Y. Park, S.H. Ahn, K.-H. Han, W.H. Gerlich and M.P. Windisch 289

#### Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells

J. Dias, J. Hengst, T. Parrot, E. Leeansyah, S. Lunemann, D.F.G. Malone, S. Hardtke, O. Strauss, C.L. Zimmer, L. Berglin, T. Schirdewahn, S. Ciesek, N. Marquardt, T. von Hahn, M.P. Manns, M. Cornberg, H.-G. Ljunggren, H. Wedemeyer, J.K. Sandberg and N.K. Björkström 301

## Transplantation

#### Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study

D. Haldar, B. Kern, J. Hodson, M.J. Armstrong, R. Adam, G. Berlakovich, J. Fritz, B. Feurstein, W. Popp, V. Karam, P. Muiesan, J. O'Grady, N. Jamieson, S.J. Wigmore, J. Pirenne, S.A. Malek-Hosseini, E. Hidalgo, Y. Tokat, A. Paul, J. Pratschke, M. Bartels, P. Trunecka, U. Settmacher, M. Pinzani, C. Duvoux, P.N. Newsome, S. Schneeberger and all Contributing Centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA) 313

## Cancer

Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma

C. Gérard, M. Di-Luoffo, L. Gonay, S. Caruso, G. Couchy, A. Lorient, D. Castven, J. Tao, K. Konobrocka, S. Cordi, S.P. Monga, E. Hanert, J.U. Marquardt, J. Zucman-Rossi and F.P. Lemaigre 323

Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma

D.-P. Chen, W.-R. Ning, Z.-Z. Jiang, Z.-P. Peng, L.-Y. Zhu, S.-M. Zhuang, D.-M. Kuang, L. Zheng and Y. Wu 333

## Molecular and Cell Biology

Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity

A.W. Overeem, K. Klappe, S. Parisi, P. Klöters-Planchy, L. Mataković, M. du Teil Espina, C.A. Drouin, K.H. Weiss and S.C.D. van IJzendoorn 344

## Cholestasis and Autoimmune Diseases

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

M.H. Harms, H.R. van Buuren, C. Corpechot, D. Thorburn, H.L.A. Janssen, K.D. Lindor, G.M. Hirschfield, A. Parés, A. Floreani, M.J. Mayo, P. Invernizzi, P.M. Battezzati, F. Nevens, C.Y. Ponsioen, A.L. Mason, K.V. Kowdley, W.J. Lammers, B.E. Hansen and A.J. van der Meer 357

## Genetic and Metabolic Diseases

Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic *ABHD5* mutations

L. Youssefian, H. Vahidnezhad, A.H. Saeidian, S. Pajouhanfar, S. Sotoudeh, P. Mansouri, D. Amirkashani, S. Zeinali, M.A. Levine, K. Peris, R. Colombo and J. Uitto 366

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease

A. Srivastava, R. Gailer, S. Tanwar, P. Trembling, J. Parkes, A. Rodger, D. Suri, D. Thorburn, K. Sennett, S. Morgan, E.A. Tsochatzis and W. Rosenberg 371

The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content

Y. Gepner, I. Shelef, O. Komy, N. Cohen, D. Schwarzfuchs, N. Bril, M. Rein, D. Serfaty, S. Kenigsbuch, H. Zelicha, A. Yaskolka Meir, L. Tene, A. Bilitzky, G. Tsaban, Y. Chassidim, B. Sarusy, U. Ceglarek, J. Thiery, M. Stumvoll, M. Blüher, M.J. Stampfer, A. Rudich and I. Shai 379

New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD

J. Boursier, M. Guillaume, V. Leroy, M. Irlès, M. Roux, A. Lannes, J. Foucher, F. Zuberbuhler, C. Delabaudière, J. Barthelon, S. Michalak, J.-B. Hiriart, J.-M. Peron, T. Gerster, B. Le Bail, J. Riou, G. Hunault, W. Merrouche, F. Oberti, L. Pelade, I. Fouchard, C. Bureau, P. Calès and V. de Ledinghen 389

## REVIEWS

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

G. Raimondo, S. Locarnini, T. Pollicino, M. Levrero, F. Zoulim, A.S. Lok and the Taormina Workshop on Occult HBV Infection Faculty Members 397

Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies

P. Jiang, K.C.A. Chan and Y.M.D. Lo 409

## SPECIAL SECTION

### Clinical Trial Watch

Current and innovative emerging therapies for porphyrias with hepatic involvement

A. Fontanellas, M.A. Ávila, K.E. Anderson and J.-C. Deybach 422

## LETTERS TO THE EDITOR

Convalescent plasma therapy for persistent hepatitis E virus infection

M. Ankcorn, J. Gallacher, S. Ijaz, Y. Taha, H. Harvala, S. MacLennan, E.C. Thomson, C. Davis, J.B. Singer, A. da Silva Filipe, K. Smollett, M. Niebel, M.G. Semple, R.S. Tedder and S. McPherson 434

Role of HGF for reprogramming human liver progenitor cells: Non-essential but stimulative supplement

Y. Huang, T. Miyoshi, Y. Sakai, T. Hara, W.-I. Gu and S. Eguchi 438

Reply to: "Role of HGF for reprogramming human liver progenitor cells: Non-essential but stimulative supplement"

S.B. Lee, Y. Kim, K. Kang, V.M. Factor, D. Seo, J.-H. Yim, D. Choi and J. Jeong 439

Normothermic regional perfusion – What is the benefit?

A. Schlegel, P. Muiesan and P. Dutkowski 441

Reply to: "Normothermic regional perfusion – What is the benefit?"

A.J. Hessheimer, E. Coll, P. Ruiz, M. Gastaca, J.I. Rivas, M. Gómez, B. Sánchez, J. Santoyo, P. Ramírez, P. Parrilla, L.M. Marín, M.Á. Gómez-Bravo, J.C. García-Valdecasas, J. López-Monclús, A. Boscá, R. López-Andújar, Y. Fundora-Suárez, J. Villar, Á. García-Sesma, C. Jiménez, G. Rodríguez-Laíz, L. Lladó, J.C. Rodríguez, M. Barrera, R. Charco, J.Á. López-Baena, J. Briceño, F. Pardo, G. Blanco, D. Pacheco, B. Domínguez-Gil, V. Sánchez Turrión and C. Fondevila 443

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules – A response

S. Pol, H. Fontaine, F. Carrat, and on the behalf of the ANRS/AFEP Hepather Study group 446

Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules – A response"

V. Sapena, J. Rios, F. Torres, Z. Mariño, X. Forns, J. Bruix and M. Reig 447

---

## Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease, by A. Srivastava *et al.* on pp. 371–378 in this issue.

Cover design: 3D representation of a referral pathway. Image by infografx – stock.adobe.com.